Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III single-arm study of tasurgratinib in previously treated FGFR2 fusion/rearranged unresectable or metastatic cholangiocarcinoma
CTR20262724Phase 3Active
- Sponsor
- Eisai Co., Ltd.
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tasurgratinib in cholangiocarcinoma (CCA), sponsored by Eisai Co., Ltd.. Started Jul 2026; status: active.
02
Drugs
tasurgratinib
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on CTR20262724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262724.